Long-term outcome of short-course high-dose glucocorticoids for SARS: a 17-year follow-up in SARS survivors
Abstract
Use of high-dose glucocorticoids for COVID-19 (caused by SARS-CoV-2) is controversial because of safety concerns. We examined the long-term consequences of glucocorticoid use in severe acute respiratory syndrome (caused by SARS-CoV-1) survivors. Results showed that high-dose glucocorticoids greatly increased the long-term risk of avascular necrosis but not other major diseases.
Citation
Sing, C.-W., Tan, K. C. B., Wong, I. C. K., Cheung, B. M. Y., & Cheung, C.-L. (2020, July 15). Long-term Outcome of Short-course High-dose Glucocorticoids for Severe Acute Respiratory Syndrome (SARS): A 17-Year Follow-up in SARS Survivors. Clinical Infectious Diseases. Oxford University Press (OUP). http://doi.org/10.1093/cid/ciaa992
Resource Type
Addition Details
Date:
2020-07-16
Wave of COVID:
3rd
Category:
Source URL:
Share